Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $8 to $7.
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $8 to $7.